Clinical Trial Update: Platform Study of Circulating Tumor DNA Directed Adjuvant Chemotherapy in Colon Cancer (KCSG CO22-12) [Phase 3]

View source ↗

Summary

A Phase 3 platform trial (KCSG CO22-12) is evaluating circulating tumor DNA-directed adjuvant chemotherapy for colon cancer and is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colon Cancer

Snippet

Sponsor: Seoul National University Hospital | Conditions: Colon Cancer | Phase 3 | Status: RECRUITING